Subcutaneous bortezomib incorporated into the bortezomib-thalidomide-dexamethasone regimen as part of front-line therapy in the context of autologous stem cell transplantation for multiple myeloma

MeSH terms

• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols / adverse effects
• Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
• Boronic Acids / administration & dosage
• Bortezomib
• Dexamethasone / administration & dosage
• Female
• Hematopoietic Stem Cell Transplantation*
• Humans
• Male
• Middle Aged
• Multiple Myeloma / diagnosis
• Multiple Myeloma / therapy*
• Peripheral Nervous System Diseases / etiology
• Prospective Studies
• Pyrazines / administration & dosage
• Thalidomide / administration & dosage
• Transplantation, Autologous
• Treatment Outcome